Last updated 2026-07-26
- Went public on TASE, Mar 2016
- Public offering of $140k on TSX Venture Exchange, Dec 2025
- Public offering of $350k on TSX Venture Exchange, Oct 2025
Total raised
$3.0M
Last: Public Offering 2025-12
Stage
Mature
Founded
2007
Headcount
4
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
Vaxil BioTherapeutics is a clinical-stage Israeli immunotherapy biotech company focused on developing immunotherapeutic products, including long peptide vaccines and antibodies, to treat cancer and infectious diseases. The company's core technology, VaxHit, utilizes signal peptide domains in selected targets as core antigens. Vaxil's lead product, ImMucin, has received EMA and FDA orphan drug designation for multiple myeloma and has successfully completed a phase 1/2 clinical trial. The company also develops anti-MUC1 SP antibodies (SPmAb-2.1 and SPmAb-6) and a vaccine against mycobacterium tuberculosis, MTBuVax, which is in preclinical studies.
Funding history · 2 rounds · $3.0M total
9 events/rounds · $3.0M Total Funding: $754K in Public Equity, $3.0M in Debt
Dec 2025
Jul 2013
★ Yorkville Advisers LLC
Headcount over time
4 employees (2026-09) · 1 point
Offices
Ness Ziona, Israel · HQ / main office
Show all offices (1 more)
- Toronto, Canada
Q&A
- What is Vaxil BioTherapeutics' primary focus?
- Vaxil BioTherapeutics is a clinical-stage Israeli immunotherapy biotech company focused on developing immunotherapeutic products, including long peptide vaccines and antibodies, to treat cancer and infectious diseases.
- What is the status of Vaxil BioTherapeutics' lead product, ImMucin?
- Vaxil BioTherapeutics' lead product, ImMucin, has received EMA and FDA orphan drug designation for multiple myeloma and has successfully completed a phase 1/2 clinical trial. The company is also performing an additional phase 1/2 study with ImMucin in metastatic breast cancer patients.
- When was Vaxil BioTherapeutics founded?
- Vaxil BioTherapeutics was founded in February 2007.
- What is the employee count for Vaxil BioTherapeutics?
- Vaxil BioTherapeutics has 1-10 employees.
- What is Vaxil BioTherapeutics' core technology?
- Vaxil BioTherapeutics' core technology, VaxHit, utilizes signal peptide domains in selected targets as core antigens.
- Has Vaxil BioTherapeutics pursued a COVID-19 vaccine?
- In March 2020, Vaxil BioTherapeutics commenced a preclinical COVID-19 vaccine trial and filed an additional COVID-19 patent.
- What was Vaxil BioTherapeutics' most recent public offering amount?
- In December 2025, Vaxil BioTherapeutics had a public offering that raised $140,000.
- What is the status of Vaxil BioTherapeutics' vaccine against mycobacterium tuberculosis?
- Vaxil BioTherapeutics' vaccine against mycobacterium tuberculosis, MTBuVax, is currently in preclinical studies.
- What was the total amount raised by Vaxil BioTherapeutics through funding rounds?
- Vaxil BioTherapeutics has raised a total of $6,350,000 through funding rounds.
Team · 6
Gadi Levin
CEO, Chairman of the Board, CFO
Alan Rootenberg
CFO
Simon Igelman
Board Member
Saeid Babaei
Chairman
Riva Kovjazin
R&D
Terry Plasse
Clinical Affairs
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B
Highlights
1 Patents
Tags
immunologybiotechnologytherapeuticsbiopharmaceuticalpublic-healthcancerinfectious-diseaseoncologypharmaceuticalscancer-therapypharma-companiesvaccines
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | vaxil-bio.com/cgi-sys/suspendedpage.cgi |
|---|---|
| linkedin.com/company/10579659 | |
| facebook.com/Vxlbio | |
| YouTube | youtube.com/channel/UC4i330YiJG7UplCSMluxMOw |
| instagram.com/vaxilbio |
Identifiers & details
| Founded | 2007-2 |
|---|---|
| Employees (exact) | 4 |
| Offices | Toronto |
| Status reason | Public on TASE on Mar 2016; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2016-03 | TASE | ||
| Public Offering | 2019-10 | TSX Venture Exchange | VXL | |
| Public Offering | 2020-06 | TSX Venture Exchange | VXL | |
| Public Offering | 2020-11 | TSX Venture Exchange | VXL | |
| Public Offering | 2020-12 | TSX Venture Exchange | VXL | $264K |
| Public Offering | 2025-10 | TSX Venture Exchange | VXL | $350K |
| Public Offering | 2025-12 | TSX Venture Exchange | VXL | $140K |
Radar intelligence
Patents
| EPO | 5 |
|---|
Web history (Wayback)
| Domain | vaxil-bio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513861351 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2006-08-06 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 4 — people (3), shares_capital (1) |
| Registered address | אבו בכר 1 ג'לג'וליה |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-16 | עדכון דירקטורים-הסרת דירקטור |
| 2026-06-16 | העברת מניות |
| 2026-06-16 | עדכון דירקטורים-הוספת דירקטור |
| 2025-09-04 | עדכון בעלי תפקידים |